{"id":62566,"date":"2026-04-07T22:01:29","date_gmt":"2026-04-07T14:01:29","guid":{"rendered":"https:\/\/flcube.com\/?p=62566"},"modified":"2026-04-07T22:01:30","modified_gmt":"2026-04-07T14:01:30","slug":"aidea-pharmas-novel-hiv-1-capsid-inhibitor-acc085-cleared-for-prep-trial-in-china-targeting-long-acting-prevention","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62566","title":{"rendered":"Aidea Pharma\u2019s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention"},"content":{"rendered":"\n<p><strong>Jiangsu Aidea Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688488:SHA\">SHA: 688488<\/a>) has secured <strong>clinical trial approval from China\u2019s National Medical Products Administration (NMPA)<\/strong> for <strong>ACC085<\/strong>, its <strong>Category 1 novel chemical entity<\/strong>, as a <strong>pre-exposure prophylaxis (PrEP)<\/strong> option for <strong>adults and adolescents (\u226535 kg) at risk of HIV-1 infection<\/strong>.<\/p>\n\n\n\n<p>ACC085 is a first-in-class <strong>HIV-1 capsid function inhibitor<\/strong> that disrupts multiple stages of the viral life cycle by binding to the <strong>interface between capsid protein subunits<\/strong>\u2014a mechanism distinct from current antiretrovirals. The molecule blocks <strong>capsid-mediated nuclear import of proviral DNA<\/strong>, <strong>viral assembly and release<\/strong>, and <strong>proper capsid core formation<\/strong>, offering a high barrier to resistance.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-amp-regulatory-milestone\">Development &amp; Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Name<\/strong><\/td><td>ACC085<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>NMPA Category 1 (innovative new drug)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>HIV-1 capsid function inhibitor (multi-step disruption)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Pre-exposure prophylaxis (PrEP) for HIV-1<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>Adults and adolescents \u226535 kg at risk of HIV-1 exposure<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NMPA IND approved for Phase I\/II clinical study<\/td><\/tr><tr><td><strong>Origin<\/strong><\/td><td>Fully indigenous R&amp;D by Aidea Pharma<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-scientific-differentiation\">Scientific Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Multi-Stage Inhibition<\/strong>: Unlike nucleoside analogs or integrase inhibitors, ACC085 targets the <strong>structural capsid protein<\/strong>, interfering with <strong>early (nuclear entry)<\/strong> and <strong>late (assembly\/release)<\/strong> viral processes simultaneously.<\/li>\n\n\n\n<li><strong>Broad-Spectrum Activity<\/strong>: Preclinical data show potent efficacy against <strong>diverse HIV-1 strains<\/strong>, including <strong>clinical isolates<\/strong> and <strong>drug-resistant variants<\/strong> (e.g., NNRTI-, PI-, and INSTI-resistant).<\/li>\n\n\n\n<li><strong>Long-Acting Potential<\/strong>: Favorable <strong>pharmacokinetic profile<\/strong> supports development of <strong>extended-release formulations<\/strong> (e.g., monthly oral or injectable), addressing adherence challenges in current daily PrEP regimens.<\/li>\n\n\n\n<li><strong>In Vivo Efficacy<\/strong>: Demonstrated <strong>strong preventive and protective effects<\/strong> in non-human primate and humanized mouse models of HIV-1 infection.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-public-health-amp-commercial-outlook\">Public Health &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Epidemiological Need<\/strong>: China reports <strong>~100,000 new HIV infections annually<\/strong>, with rising incidence among key populations (MSM, adolescents); only <strong>two WHO-recommended PrEP options<\/strong> currently available domestically.<\/li>\n\n\n\n<li><strong>Market Gap<\/strong>: No long-acting or capsid-targeting PrEP approved in China; ACC085 could become the <strong>first homegrown next-generation prevention agent<\/strong>.<\/li>\n\n\n\n<li><strong>Global Relevance<\/strong>: Capsid inhibitors (e.g., Lenacapavir) are gaining traction worldwide; ACC085 positions Aidea as a potential <strong>low-cost, scalable alternative<\/strong> for middle-income markets.<\/li>\n\n\n\n<li><strong>Next Steps<\/strong>: Aidea plans to initiate a <strong>Phase I safety and PK study<\/strong> in Q3 2026, followed by a <strong>Phase IIb proof-of-concept PrEP efficacy trial<\/strong> in high-risk cohorts.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and market potential. Actual results may vary due to trial outcomes, safety findings, and evolving public health policies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688488_20260407_2CAD.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688488_20260407_2CAD.\"><\/object><a id=\"wp-block-file--media-0b529497-4daf-46a1-aae4-59ba70b84e94\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688488_20260407_2CAD.pdf\">688488_20260407_2CAD<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688488_20260407_2CAD.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0b529497-4daf-46a1-aae4-59ba70b84e94\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) has secured clinical trial approval from China\u2019s National&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[619,62,631,988],"class_list":["post-62566","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-aidea-pharmaceutical","tag-clinical-trial-approval-initiation","tag-hiv-aids-care","tag-sha-688488"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Aidea Pharma\u2019s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) has secured clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for ACC085, its Category 1 novel chemical entity, as a pre-exposure prophylaxis (PrEP) option for adults and adolescents (\u226535 kg) at risk of HIV-1 infection.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62566\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aidea Pharma\u2019s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) has secured clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for ACC085, its Category 1 novel chemical entity, as a pre-exposure prophylaxis (PrEP) option for adults and adolescents (\u226535 kg) at risk of HIV-1 infection.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62566\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-07T14:01:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-07T14:01:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62566#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62566\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Aidea Pharma\u2019s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention\",\"datePublished\":\"2026-04-07T14:01:29+00:00\",\"dateModified\":\"2026-04-07T14:01:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62566\"},\"wordCount\":402,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Aidea Pharmaceutical\",\"Clinical trial approval \\\/ initiation\",\"HIV \\\/ AIDS care\",\"SHA: 688488\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62566#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62566\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62566\",\"name\":\"Aidea Pharma\u2019s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-07T14:01:29+00:00\",\"dateModified\":\"2026-04-07T14:01:30+00:00\",\"description\":\"Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) has secured clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for ACC085, its Category 1 novel chemical entity, as a pre-exposure prophylaxis (PrEP) option for adults and adolescents (\u226535 kg) at risk of HIV-1 infection.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62566#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62566\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62566#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aidea Pharma\u2019s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Aidea Pharma\u2019s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) has secured clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for ACC085, its Category 1 novel chemical entity, as a pre-exposure prophylaxis (PrEP) option for adults and adolescents (\u226535 kg) at risk of HIV-1 infection.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62566","og_locale":"en_US","og_type":"article","og_title":"Aidea Pharma\u2019s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention","og_description":"Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) has secured clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for ACC085, its Category 1 novel chemical entity, as a pre-exposure prophylaxis (PrEP) option for adults and adolescents (\u226535 kg) at risk of HIV-1 infection.","og_url":"https:\/\/flcube.com\/?p=62566","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-07T14:01:29+00:00","article_modified_time":"2026-04-07T14:01:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62566#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62566"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Aidea Pharma\u2019s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention","datePublished":"2026-04-07T14:01:29+00:00","dateModified":"2026-04-07T14:01:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62566"},"wordCount":402,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Aidea Pharmaceutical","Clinical trial approval \/ initiation","HIV \/ AIDS care","SHA: 688488"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62566#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62566","url":"https:\/\/flcube.com\/?p=62566","name":"Aidea Pharma\u2019s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-07T14:01:29+00:00","dateModified":"2026-04-07T14:01:30+00:00","description":"Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) has secured clinical trial approval from China\u2019s National Medical Products Administration (NMPA) for ACC085, its Category 1 novel chemical entity, as a pre-exposure prophylaxis (PrEP) option for adults and adolescents (\u226535 kg) at risk of HIV-1 infection.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62566#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62566"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62566#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Aidea Pharma\u2019s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62566"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62566\/revisions"}],"predecessor-version":[{"id":62568,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62566\/revisions\/62568"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}